Special NoticePosted Nov 27, 2024·Original deadline passed (Sep 20). See latest amendment for current deadline.

6505--Supply, Axumin-Axumin + Cerianna Medicines - Nuclear Med, CLE

Veterans Affairs · 250-NETWORK CONTRACT OFFICE 10 (36C250)

Stage
Early notice (sources sought, presolicitation or special notice)
NAICS
325412
Value
Not stated
Solicitation
36C25024Q1072
Set-aside
None stated
PSC
6505
Place
Not stated
Contact
Gina P. Crank (gina.crank@va.gov)
Loading your pipeline and notes…
CSV Email

Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.

Where this opportunity stands

Every notice posted under solicitation 36C25024Q1072 in this department, oldest first.

Early notice
  • Sep 14, 2024
    Special Notice
    Open
  • Nov 27, 2024 · this notice
    Special Notice
Solicitation
None posted
Award
  • Nov 27, 2024
    Award Notice
    TRILLAMED LLC · $135K
    Open

Next steps for this stage

Standard steps for the notice type; not advice about this buyer.

  • Answer the notice: this is when the requirement can still be shaped.
  • Contact the contracting officer named on the notice.
  • Check who won similar work; they are the likely bidders.

What the notice says

Page 1 of 1 36C25023Q1127 SPECIAL NOTICE NOTICE OF INTENT TO SOLE SOURCE Axumin, Amyvid and Cerianna Doses The Department of Veterans Affairs, The Louis Stokes Cleveland Department of Veteran Affairs Medical Center, 10701 East Boulevard, Cleveland, Ohio 44106 intends to solicit and negotiate with only one source under the authority of FAR 6.302-1(a)(2), Only one responsible source and no other supplies or services will satisfy agency requirements. The VA intends to solicit and negotiate with PetNet Solutions, a Siemens Company, 810 Innovation Drive, Knoxville, TN 37932, and with TrillaMed, 301… (show all)

00 Telegraph Road, Bingham Farm, MI 48025 an authorized distributor for Axumin, Amyvid Cerianna Doses. The Nuclear Medicine Service at the Louis Stokes Cleveland VA Medical Center is interested in using state-of-the-art radiopharmaceuticals for diagnostic patient care. Axumin is used in the diagnosis of recurrent prostate cancer, Cerianna breast cancer estrogen receptor (ER)-positive lesions, and Amyvid is helpful in the diagnosis of Alzheimer s disease. These radiopharmaceuticals are proprietary. The base dose is manufactured by Blue Earth Diagnostics Inc. and then it is made radioactive and distributed by PETNET Solutions. Due to the radioactive nature of the doses and their relatively short half-life (each has a 10-hour shelf life), a local radiopharmacy must be utilized. The Government believes that only these business can satisfy the agency requirements and intends to negotiate with only one source under the authority of FAR 6.302-1(a)(2), Only one responsible source and no other supplies or services will satisfy agency requirements. Other persons may identify their interest and capability to respond to this requirement by 18SEP24 at 1700 HRS EST. Such capabilities information will be used solely for the purpose of determining whether or not to conduct this procurement on a competitive basis.� All information shall be furnished at no cost or obligation to the Government.� A determination by the Government not to open the requirement to competition based upon responses to this notice is solely within the discretion of the Government. No solicitation is available at this time. � All inquiries must be submitted by email to Don Caldwell at don.caldwell@va.gov Enter RFQ 36C25024Q1072 Axumin, Amyvid and Cerianna Doses in the email subject line.

Who won similar work

5 award notices on SAM.gov in the last 24 months. Matched by: Same office (250-NETWORK CONTRACT OFFICE 10 (36C250)), same product/service code (PSC) 6505 and NAICS 325412.

Single-winner award sizes (5): middle half $559K to $5.2M, median $700K; range $558K to $5.4M.

WinnerAwardsValueLast
PROGENICS PHARMACEUTICALS INC2$6.0MMay 8, 2026
SOFIE Co. DULLES 201662$1.3MOct 1, 2026
RLS (USA) INC.1$5.2MOct 1, 2026

Value counts new single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling (same contract, or the same office, day and amount); that ceiling is not one company's win, so it is not added in. Contract modifications are not new awards and are not added in either. Notices whose amount is a placeholder such as $999,999,999 are not added in. Revenue next to a ticker is the company's revenue over the latest 12 months in its SEC filings.

Latest awards

Competitive landscape

For the 3 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.

  • 0 of these past winners lobbied Veterans Affairs, Dept of (VA) since 2024 (0 filings)
  • 0 of their lobbyists list a past Veterans Affairs, Dept of (VA) job
  • No corporate PAC money from them to the overseeing committees since 2024
  • 0 foreign-agent (FARA) registrations
See who and the source records with Pro

Policy around it

Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.

  • 0 bills named on the past winners' lobbying filings
  • 25 rules from the department in the last 12 months
  • 0 executive orders naming the agency in the last 12 months
See who and the source records with Pro

Market

For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.

  • 0 of the past winners are listed companies
  • 0 insider buys and 0 insider sells at them in the last 90 days
See who and the source records with Pro

Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.

Companies are matched to tickers by exact name, including the subsidiaries a company lists in its SEC filings. A company we could not match shows no market rows; that is a miss, not a finding.